CompaniesJobsClinical TrialsTrendsWhere It's LegalProvidersConferencesResources

Overview

BiotechPhase 3LSDMDMAHiring

Formerly MindMed, rebranded to Definium Therapeutics in January 2026. Developing DT120 (LSD) for generalized anxiety disorder and major depressive disorder. Three Phase 3 readouts expected in 2026.

Visit Website

New York, NY

4
Clinical Trials
2019
Founded
80
Employees
12
Open Roles

Open Positions(12)

Director, Market Research, Competitive Intelligence & Forecasting
Remote
Director, Medical Marketing
Remote
Director, Tax
Hybrid
Manager, Data & Analytics
Remote
Regional Director, Site Engagement & Access
Remote
Associate Director, Brand Counsel
Remote
Director, Medical Information
Remote
Sr. Director, Sales Training
Remote
Director, Field Operations
Remote
Senior Clinical Trial Manager
Remote
Associate Director, Statistical Programming
Remote
Director, Supply and Distribution Quality
Remote

Research Areas

Anxiety

Clinical Pipeline(4)

Active, Not Recruiting·Phase 3·LSD

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

PlaceboGeneralized Anxiety Disorder
NCT06809595
Recruiting·Phase 2·MDMA

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))Autism Spectrum Disorder
NCT07303907
Completed·Phase 2·LSD

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

MM120ADHD
NCT05200936
Completed·Phase 2·LSD

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

MM120Anxiety Generalized
NCT05407064